Portfolio

Amber Bio is pioneering new RNA editing modalities to treat previously undruggable patient populations.

INDICATIONS
Undisclosed

MODALITY
Multi-kb RNA-editing platform

STAGE
Discovery/Preclinical

Fund
Core Fund

Atsena Therapeutics is developing novel AAV-based gene therapies for monogenic inherited retinal diseases.

INDICATIONS
LCA1, XLRS, USH1B, STGD

MODALITY
Novel AAV-based gene therapy

STAGE
Clinical

Fund
Core Fund

Beacon Therapeutics is developing genetic therapies for the treatment of rare and prevalent ocular diseases.

INDICATIONS
XLRP, Dry AMD

MODALITY
AAV-based Gene Therapy 

Stage
Clinical

Private/Public
Private

Fund
Core Fund

Nacuity is developing targeted therapies aimed at preventing oxidative tissue damage, a driver of blinding eye disease.

INDICATIONS
RP, Nephropathic Cystinosis

MODALITY
Oral small molecule anti-oxidant

STAGE
Clinical

Fund
Core Fund

NVasc is an early-stage ophthalmology company focused on treating the dry AMD spectrum through choroidal and retinal revascularization.

INDICATIONS
Dry AMD/GA

MODALITY
LIFR-agonist for revascularization

STAGE
Discovery/Preclinical

Fund
Discovery Fund

Opus is a mission based AAV gene therapy company created for treatment of inherited retinal diseases

INDICATIONS
LCA5, BEST1, RDH12, MERTK

MODALITY
AAV-based gene therapy

STAGE
Clinical

Private/Public
Public

Fund
Core Fund

Perceive Bio aims to target risk alleles for dry AMD and GA, target regulation of the complement system, and key retinal neuroprotective pathways.

INDICATIONS
Dry AMD/GA, Neuroprotection

MODALITY
AAV-based gene therapy

STAGE
Clinical

Private/Public
Private

Fund
Core Fund

Perceive Pharma is pioneering novel small molecule neuroprotective therapeutics, with lead pipeline programs in glaucoma and other ophthalmic diseases

INDICATIONS
Glaucoma, Undisclosed

MODALITY
Small molecule neuroprotection

STAGE
Preclinical

Private/Public
Private

Fund
Core Fund

CheckedUp is a physician-founded, physician-run patient education company offering tech-enabled patient engagement solutions.

INDICATIONS
Healthcare Technology Platform

Fund
Core Fund

Acquired by Rockbridge

ProQR is developing unique RNA therapies for severe rare and common diseases.

INDICATIONS
CEP290, USH2A

MODALITY
ASO (RNA) platform

STAGE
Clinical

Fund
Core Fund

Ophthalmic asset divestiture

SalioGen is developing a novel mammallian-derived enzyme, saliogase, for editing, replacing or augmenting DNA without double-strand breaks or relying on host repair or homologous recombination.

INDICATIONS
STGD

MODALITY
SalioGase editing platform

STAGE
Discovery

Private/Public
Private

Fund
Core Fund

Dissolved

Stargazer was developing a visual cycle modulator aimed at reducing pathologic accumulation of cytotoxic retinoids in the retina.

INDICATIONS
STGD, Dry AMD

MODALITY
Small Molecule

Fund
Discovery Fund

Solvent Dissolution

Vedere Bio I  leveraged a mutation agnostic optogenetic technology with the aim of restoring vision due to photoreceptor cell death. 

INDICATIONS
Late-Stage RP (mutation independent)

MODALITY
Optogenetic Platform

STAGE
Preclinical

Fund
Core Fund

Acquired by Novartis

Vedere Bio II 

INDICATIONS
Late-Stage RP (mutation independent)

MODALITY
Optogenetic Platform

STAGE
Preclinical

Fund
Core Fund

Dissolved